This page is available in multiple languages
EnterNext welcomes Poxel on Euronext in Paris
Thomas Kuhn, CEO of Poxel, rings the opening bell.
Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes.
At the end of 2014, the group had 6 products including 1 in phase II of clinical development (Imeglimin), 1 in phase of preclinical development (PXL770) and 4 in research phase.